Well-healthcare Raises ￥100 Million in Extended Series A Round

(VCBeat) July. 29, 2021 -- In June 2021, Well-healthcare Technologies Co., Ltd. ("Well-healthcare") extended the Series A investment round by an additional ￥100 million. This round of financing was jointly led by Longmen Capital and Tianhui Capital, with participation from Lotus Lake Ventures and Jiyang Talent Fund, and the existing investor Thunderstorm Venture Capital. WinX Capital acted as the exclusive financial advisor.

After completion of this round of financing, Well-healthcare will further develop the multiple-omics accurate diagnosis platform based on "3T", promote real-world clinical researches and the development of precise diagnosis products based on multiple omics, meet the demand of clinical application in different scenarios, build the high-throughput mass spectrometry industry chain, and accelerate the industrialization and marketization of main businesses and products.

Well-healthcare's 3T-based multi-omics precision diagnosis platform consists of an innovative diagnostic methodology system based on MT (Materials Technology), BT (Biotechnology) and IT (Information Technology). It has successfully developed a high-throughput mass spectrometry platform and an artificial olfactory system platform at the international forefront level, and built a product development and application system that is suitable for various types of sample, multi-omics tests and diversified clinical scenarios.

Well-healthcare has cooperated with leaders in the industry to develop the world's first sets of peptides identification in tumors, the ClinMS-Plat^®Ⅰ mass spectrometry diagnostics system, which is going to be launched. Besides, Well-healthcare built the first diagnostic reagent and AI-based liquid biopsy diagnosis model for colorectal cancers, which is called Bio-pSi®, with an accuracy over 90%.

Founded in 2017, Longman Capital focuses on investments in companies engaged in innovative medicine and life science technology in early and early-growth stages. The core team has a wealth of operation and investment experience in the pharmaceutical field. At present, it has initiated and established the third-phase fund, with a management scale of 2 billion yuan.

Founded in 2001, Lotus Lake Ventures is an investment firm committed to investing in science and technology innovation enterprises, focusing on high-tech enterprises with core competitiveness in the initial stage and growth stage in the fields of information technology, life science and clean technology, etc.